TOVX therivabio.com: Enterprise Value to EBITDA Ratio

Graphic logo of Theriva Biologics (TOVX)

The price action of Theriva Biologics, Inc. (TOVX) reflects an EV/EBITDA of 0.00, while the company finances the development of anti-tumor viruses through grants. The brand's high scientific potential enables the development of protein blocking methods for gastrointestinal tract treatment. To eliminate human error during culture growth, automated bioreactors in sterile booths are being implemented, minimizing the risk of medium contamination.

Synthetic Biologics - TOVX Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/17/2026)

Summary analytical data breakdowns for Synthetic Biologics (TOVX)

- stock price and consensus target price:
Fundamental company analysis:TOVX (Theriva Biologics)
Original product of Theriva Biologics Inc

To isolate fundamental stability from market noise, it is necessary to use a metric that compares the total enterprise value (including debt) of Theriva Biologics, Inc. (TOVX) with its operating profit before interest, taxes, depreciation, and amortization. This ratio determines the real value of assets relative to the generated cash flow, making it possible to identify overvaluation or stagnation within the company. By analyzing the EV/EBITDA valuation trend, an investor can assess the efficiency of attracting venture capital to overcome stringent FDA regulatory barriers during the development of oncolytic viruses.

Competitor analysis for Theriva Biologics, Inc.

ImmunityBio Inc - Enterprise Value to EBITDA Ratio|Immunocore (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (Arcus Biosciences)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iovance.com|Enterprise Value to EBITDA Ratio immatics.com (IMTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor Inc (XNCR)|Enterprise Value to EBITDA Ratio Compass Bio CMPX|Replimune Group Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Lyell Pharma LYEL|IPHA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PYXS (Pyxis Oncology) - Enterprise Value to Operating Income Before Depreciation|cgen.com (CGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA IO Biotech Corp (IOBT)|Enterprise Value to EBITDA Ratio STRO|INKT - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio HOWL (Werewolf Therapeutics)|Enterprise Value to Operating Income Before Depreciation Ratio IMMX|EV/EBITDA Multiple ALXO (ALX Oncology)|cuebiopharma.com (CUE) - Company Value to EBITDA|PDS Biotechnology Corp - EV/EBITDA Multiple|Company Value to EBITDA Sonnet BioTherapeutics Holdings|MAIA Biotechnology (MAIA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Liminatus Pharma - Business Value to Operating Income Before Depreciation|LVTX (Lava Tx) - EV/EBITDA Multiple|EV/EBITDA Multiple NextCure Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization leaptx.com (LPTX)|INTS: Company Value to Operating Income Before Depreciation Ratio|Sensei Biotherapeutics, Inc. - Enterprise Value to EBITDA Ratio|Gritstone Bio (GRTS) - Company Value to EBITDA|KA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NEXI (NexImmune) - Enterprise Value to Operating Income Before Depreciation|TSBX (Turnstone Biologics Corp.) - Enterprise Value to EBITDA Ratio|Vaccinex, Inc (VCNX) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harpoon Therapeutics